$HLVX
HilleVax, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022016497 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.577M $3.982M $2.603M
YoY Change 49.38% 117.28%
% of Gross Profit
Research & Development $13.32M $8.826M $2.500M
YoY Change -66.11% 836.33%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $17.89M $12.81M $11.31M
YoY Change -57.76% 955.89% 672.29%
Operating Profit -$17.89M -$12.81M -$11.31M
YoY Change -54.9% 955.89% 672.29%
Interest Expense $205.0K $888.0K $2.064M
YoY Change -127.93% 11000.0% 22833.33%
% of Operating Profit
Other Income/Expense, Net $1.087M -$41.12M -$56.57M
YoY Change -104.94% 8957.49% 69743.21%
Pretax Income -$16.81M -$53.93M -$67.89M
YoY Change -74.18% 4291.14%
Income Tax
% Of Pretax Income
Net Earnings -$16.81M -$53.93M -$67.89M
YoY Change -74.18% 3135.09% 4291.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$2.03 -$10.06
Diluted Earnings Per Share -$0.45 -$2.03 -$10.06
COMMON SHARES
Basic Shares Outstanding 33.43M 26.51M 6.749M
Diluted Shares Outstanding 37.32M 26.51M 6.749M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $292.1M $314.6M $111.3M
YoY Change 125.39%
Cash & Equivalents $292.1M $314.6M $111.3M
Short-Term Investments
Other Short-Term Assets $8.094M $4.893M $480.0K
YoY Change 16418.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $300.2M $319.5M $111.7M
YoY Change 131.55%
LONG-TERM ASSETS
Property, Plant & Equipment $600.0K $20.08M $176.0K
YoY Change 189.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.00K $2.788M
YoY Change -93.67%
Total Long-Term Assets $21.92M $21.73M $2.964M
YoY Change 3967.16%
TOTAL ASSETS
Total Short-Term Assets $300.2M $319.5M $111.7M
Total Long-Term Assets $21.92M $21.73M $2.964M
Total Assets $322.1M $341.2M $114.7M
YoY Change 147.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $875.0K $6.033M $4.010M
YoY Change -28.57%
Accrued Expenses $7.700M $6.419M $4.778M
YoY Change 357.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $175.3M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.633M $12.51M $282.9M
YoY Change -95.54%
LONG-TERM LIABILITIES
Long-Term Debt $4.737M $4.697M $0.00
YoY Change
Other Long-Term Liabilities $379.0K $81.00K $1.000K
YoY Change 136.88%
Total Long-Term Liabilities $5.116M $4.778M $1.000K
YoY Change 3097.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.633M $12.51M $282.9M
Total Long-Term Liabilities $5.116M $4.778M $1.000K
Total Liabilities $34.88M $38.08M $283.1M
YoY Change -81.99%
SHAREHOLDERS EQUITY
Retained Earnings -$243.8M -$227.0M -$173.1M
YoY Change
Common Stock $531.0M $530.2M $4.699M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $287.2M $303.2M -$168.4M
YoY Change
Total Liabilities & Shareholders Equity $322.1M $341.2M $114.7M
YoY Change 147.43%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$16.81M -$53.93M -$67.89M
YoY Change -74.18% 3135.09% 4291.14%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$19.55M -$13.21M -$10.72M
YoY Change 628.28% 2469.54%
INVESTING ACTIVITIES
Capital Expenditures -$185.0K $0.00
YoY Change 1133.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$2.500M
YoY Change -100.0%
Cash From Investing Activities -$185.0K $0.00 -$2.500M
YoY Change -93.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.820M 218.2M -99.00K
YoY Change -102.09%
NET CHANGE
Cash From Operating Activities -19.55M -13.21M -10.72M
Cash From Investing Activities -185.0K 0.000 -2.500M
Cash From Financing Activities -2.820M 218.2M -99.00K
Net Change In Cash -22.55M 205.0M -13.31M
YoY Change -117.41% 3092.81%
FREE CASH FLOW
Cash From Operating Activities -$19.55M -$13.21M -$10.72M
Capital Expenditures -$185.0K $0.00
Free Cash Flow -$19.36M -$13.21M
YoY Change 625.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001888012
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41365
dei Entity Registrant Name
EntityRegistrantName
HILLEVAX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0545060
dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100 - #9995
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
213-5054
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
HLVX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33427209
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
314612000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124566000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4893000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
141000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
319505000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
124707000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20075000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2221000
CY2022Q2 us-gaap Assets
Assets
341232000
CY2021Q4 us-gaap Assets
Assets
127159000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6033000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1024000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6419000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9164000
CY2022Q2 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
23000
CY2021Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
2821000
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
158276000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
35000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
32000
CY2021Q4 hlvx Warrant Liabilities Related Party
WarrantLiabilitiesRelatedParty
56445000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12510000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227762000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20790000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4697000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
81000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000
CY2022Q2 us-gaap Liabilities
Liabilities
38078000
CY2021Q4 us-gaap Liabilities
Liabilities
227916000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33427209
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9225321
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31311387
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6599886
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
530151000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4426000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-227000000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105184000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
303154000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
341232000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127159000
CY2022Q2 us-gaap Related Party Costs
RelatedPartyCosts
172000
CY2021Q2 us-gaap Related Party Costs
RelatedPartyCosts
0
us-gaap Related Party Costs
RelatedPartyCosts
1594000
us-gaap Related Party Costs
RelatedPartyCosts
15000
CY2022Q2 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
8826000
CY2021Q2 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
460000
hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
15037000
hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
727000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2500000
CY2022Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
8000
CY2021Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
219000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
34000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
384000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3982000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
753000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6585000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1951000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12808000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
1213000
us-gaap Operating Expenses
OperatingExpenses
24122000
us-gaap Operating Expenses
OperatingExpenses
2678000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12808000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1213000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24122000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2678000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
334000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
340000
CY2022Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
188000
CY2021Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
8000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
717000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
17000
CY2022Q2 us-gaap Interest Expense
InterestExpense
888000
CY2021Q2 us-gaap Interest Expense
InterestExpense
8000
us-gaap Interest Expense
InterestExpense
2952000
us-gaap Interest Expense
InterestExpense
17000
CY2022Q2 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
8818000
CY2021Q2 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
444000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
13196000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
517000
CY2022Q2 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
34396000
CY2021Q2 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
444000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
51469000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
517000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6151000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
43575000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41121000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-454000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-97694000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-535000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-53929000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1667000
us-gaap Net Income Loss
NetIncomeLoss
-121816000
us-gaap Net Income Loss
NetIncomeLoss
-3213000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26512881
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26512881
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4935738
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4935738
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16685372
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16685372
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4869690
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4869690
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-168372000
CY2022Q2 hlvx Stock Issued During Period Value Conversion Of Notes And Accrued Interest Into Common Shares
StockIssuedDuringPeriodValueConversionOfNotesAndAccruedInterestIntoCommonShares
215364000
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
100020000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
556000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-53929000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
303154000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-4320000
CY2021Q2 hlvx Stock Issued During Period Value Vesting Of Restricted Shares
StockIssuedDuringPeriodValueVestingOfRestrictedShares
1000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1667000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-5986000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
hlvx Stock Issued During Period Value Conversion Of Notes And Accrued Interest Into Common Shares
StockIssuedDuringPeriodValueConversionOfNotesAndAccruedInterestIntoCommonShares
215364000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
100020000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
828000
us-gaap Net Income Loss
NetIncomeLoss
-121816000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
303154000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2773000
hlvx Vesting Restrictions Placed On Previously Issued And Outstanding Common Stock
VestingRestrictionsPlacedOnPreviouslyIssuedAndOutstandingCommonStock
1000
hlvx Stock Issued During Period Value Vesting Of Restricted Shares
StockIssuedDuringPeriodValueVestingOfRestrictedShares
1000
us-gaap Net Income Loss
NetIncomeLoss
-3213000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-5986000
us-gaap Profit Loss
ProfitLoss
-121816000
us-gaap Profit Loss
ProfitLoss
-3213000
us-gaap Depreciation
Depreciation
1000
us-gaap Share Based Compensation
ShareBasedCompensation
828000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
13196000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
517000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
51469000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
517000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
43575000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
81000
us-gaap Paid In Kind Interest
PaidInKindInterest
21000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2500000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
-692000
hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
41000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4750000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-2531000
hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-59000
hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
550000
hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
1103000
hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
717000
hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
17000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2821000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
17000
hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
754000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23925000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1536000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230006000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
16569000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
4665000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
218102000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1751000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
191677000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
209000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
124566000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
457000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
316243000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
666000
us-gaap Interest Paid Net
InterestPaidNet
30000
hlvx Noncash Or Part Noncash Operating Lease
NoncashOrPartNoncashOperatingLease
20317000
hlvx Unpaid Initial Public Offering Costs
UnpaidInitialPublicOfferingCosts
1724000
hlvx Conversion Of Convertible Promissory Notes And Accrued Interest Into Common Stock
ConversionOfConvertiblePromissoryNotesAndAccruedInterestIntoCommonStock
215364000
hlvx Conversion Of Warrant Liability Into Equity
ConversionOfWarrantLiabilityIntoEquity
100020000
hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
70000
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.681
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5883500
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0000595
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
314612000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
316243000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022Q2 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2218351
CY2021Q2 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
3368582
hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2346789
hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2520901
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3636444
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3630752
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
60000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3481000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3582000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3686000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3782000
CY2022Q2 hlvx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
24935000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39526000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12712000
CY2022Q2 hlvx Lessee Operating Lease Tenant Improvement Reimbursements
LesseeOperatingLeaseTenantImprovementReimbursements
5989000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
20825000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
35000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20790000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
8000000
us-gaap Interest Expense Debt
InterestExpenseDebt
17000000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.029
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2022Q2 hlvx Accumulated Paid In Kind Interest Amount
AccumulatedPaidInKindInterestAmount
21000
CY2022Q2 hlvx Debt Instrument Carrying Amount Including Paid In Kind Interest
DebtInstrumentCarryingAmountIncludingPaidInKindInterest
5021000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
324000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
4697000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
137000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
303000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
313000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1680000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2654000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3974000
CY2022Q2 hlvx Principal Payments Interest Payments And Final Payment Fee
PrincipalPaymentsInterestPaymentsAndFinalPaymentFee
9061000
CY2022Q2 hlvx Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
4040000
CY2022Q2 hlvx Long Term Debt Net Of Interest Pik Interest And Back End Fee
LongTermDebtNetOfInterestPikInterestAndBackEndFee
5021000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4791550
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.929
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.929
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
556000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
828000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M28D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2625435
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
509613
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2115822
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12600497

Files In Submission

Name View Source Status
0000950170-22-016497-index-headers.html Edgar Link pending
0000950170-22-016497-index.html Edgar Link pending
0000950170-22-016497.txt Edgar Link pending
0000950170-22-016497-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hlvx-20220630.htm Edgar Link pending
hlvx-20220630.xsd Edgar Link pending
hlvx-ex31_1.htm Edgar Link pending
hlvx-ex31_2.htm Edgar Link pending
hlvx-ex32_1.htm Edgar Link pending
hlvx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hlvx-20220630_cal.xml Edgar Link unprocessable
hlvx-20220630_def.xml Edgar Link unprocessable
hlvx-20220630_pre.xml Edgar Link unprocessable
hlvx-20220630_lab.xml Edgar Link unprocessable
hlvx-20220630_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending